Management of @entity1 with primitive neuroectodermal tumors of the posterior fossa/ XXXX .

@entity1 @entity6196 @entity1313 @entity1221 @entity2946
@entity6196 of the posterior fossa/ @entity2946 ( @entity6196 ) are the most common malignant primary @entity1221 of childhood. Current approaches to therapy for @entity1 with @entity6196 are illustrative of both the advances which have been made in management of @entity1313 and the areas where increased understanding is needed. With the optimal use of surgery and radiotherapy, the majority of @entity1 with @entity6196 can be expected to be alive and free of disease 5 years after diagnosis. Based on various factors, including the age of @entity1 , the extent of the disease at the time of diagnosis and histological parameters, it is possible to stratify @entity1 with @entity6196 into 'risk' groups. It is unclear whether preoperative or postoperative factors are most predictive of outcome. @entity1 with factors predictive of a higher likelihood of disease relapse seem to benefit from treatment with chemotherapy. The amount of radiotherapy and the type and amount of chemotherapy which is most efficacious in controlling the disease has yet to be determined. @entity1 surviving @entity6196 are at high risk for endocrinologic and neuropsychologic sequelae. Multiple prospective treatment protocols are now underway, attempting to determine which therapy is best at controlling disease without causing severe long-term damage. A multidisciplinary approach is needed for the treatment of @entity1 with @entity6196 .
